Literature DB >> 1988575

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.

T Saphner1, D C Tormey, R Gray.   

Abstract

The records of 2,673 patients randomized according to seven consecutive Eastern Cooperative Oncology Group (ECOG) studies of adjuvant therapy for breast cancer were reviewed for the occurrence of vascular complications. All protocols opened and closed between June 1977 and July 1987. The objectives of the present study were (1) to compare the frequency of vascular complications among patients who received adjuvant therapy for breast cancer with patients on observation, and (2) to estimate the contribution of chemotherapy and hormonal therapy to the occurrence of venous and arterial thrombi. The frequency of thrombosis, both venous and arterial combined, was 5.4% among patients who received adjuvant therapy and was 1.6% among patients on observation (P = .0002). Premenopausal patients who received chemotherapy and tamoxifen had significantly more venous complications than those who received chemotherapy without tamoxifen (2.8% v 0.8%, P = .03). Postmenopausal patients who received tamoxifen and chemotherapy had significantly more venous thrombi than those who received tamoxifen alone (8.0% v 2.3%, P = .03) or those who were observed (8.0% v 0.4%, P less than .0001). Premenopausal patients who received tamoxifen and chemotherapy had a 1.6% frequency of arterial thrombosis, significantly more than patients who received chemotherapy alone (1.6% v 0.0%, P = .004). The frequency of arterial thrombosis among postmenopausal patients was not significantly correlated with adjuvant therapy. In conclusion, patients who received adjuvant therapy for breast cancer had a 5.4% frequency of thromboembolic complications, significantly more than those who were observed. The combination of chemotherapy and tamoxifen was associated with more venous and arterial thromboembolic complications than chemotherapy alone in premenopausal patients and with more venous thrombi than tamoxifen alone among postmenopausal patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988575     DOI: 10.1200/JCO.1991.9.2.286

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  69 in total

Review 1.  A role for antiangiogenic therapy in breast cancer.

Authors:  Marsha A Moses; Jay Harper; Cecilia A Fernández
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 2.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

Review 3.  Tamoxifen in postmenopausal women a safety perspective.

Authors:  E Robinson; G G Kimmick; H B Muss
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

4.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.

Authors:  Ana Custodio; Antonio J López-Farré; José J Zamorano-León; Petra J Mateos-Cáceres; Carlos Macaya; Trinidad Caldés; Miguel de la Hoya; Elena Olivera; Javier Puente; Eduardo Díaz-Rubio; Pedro Pérez-Segura
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-07       Impact factor: 4.553

6.  Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways.

Authors:  Robert H I Andtbacka; Gildy Babiera; S Eva Singletary; Kelly K Hunt; Funda Meric-Bernstam; Barry W Feig; Frederick C Ames; Merrick I Ross; Yvette Dejesus; Henry M Kuerer
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

Review 7.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

8.  High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.

Authors:  Russell A Moore; Nelly Adel; Elyn Riedel; Manisha Bhutani; Darren R Feldman; Nour Elise Tabbara; Gerald Soff; Rekha Parameswaran; Hani Hassoun
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

Review 9.  Thromboembolic disease in cancer patients.

Authors:  Nadia Hindi; Nazaret Cordero; Enrique Espinosa
Journal:  Support Care Cancer       Date:  2013-02-21       Impact factor: 3.603

10.  Designing the ideal selective estrogen receptor modulator--an achievable goal?

Authors:  Hugh S Taylor
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.